Update on screening in prostate cancer based on recent clinical trials

Reviews on Recent Clinical Trials

Volumn 6, Issue 1, 2011, Pages 7-15

  Sciarra, Alessandro ^a   Cattarino, Susanna ^a   Salciccia, Stefano ^a   Gentilucci, Alessandro ^a   Alfarone, Andrea ^a   Mariotti, Gianna ^a   Innocenzi, Michele ^a   Gentile, Vincenzo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Prostate neoplasm; Prostate specific antigen; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DATA BASE; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER;

CLINICAL TRIALS AS TOPIC; HUMANS; INCIDENCE; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; WORLD HEALTH;

EID: 78650959107     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488711793980165     Document Type: Article

References (39)

1. Parkin DM, Bray F, Ferlay, Pisani P. Global cancer statistics, 2002. CA cancer J Clin 2005; 55: 74-108.
2. Aus G, Abbou CC, Bolla M, et al. European Association of Urology. EAU Guidelines on prostate cancer. Eur Urol 2005; 48 546-51.
3. Collin SM, Martin RM, Metcalfe C, et al. Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008; 9(5): 445-52.
4. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
5. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9.
6. EAU. European Association of Urology Guidelines 2009.
7. American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 2000; 14: 267-72, 277-8.
8. American Cancer Society Guidelines for the early detection of cancer. [Accessed March 6, 2009, Available at http://www.cancer.org/docroot/ped/content/ped_2_3x_acs_cancer_detec tion_guidelines_36.asp.]
9. Kawachi MH, Bahnson RR, Barry M, et al. National Comprehensive Cancer Network clinical practice guidelines in oncology: prostate cancer early detection (v.2.2007). [accessed March 6, 2009, Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf].
10. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149: 185-91.
11. Scales CD Jr, Antonelli J, Curtis LH, Schulman KA, Moul JW. Prostate-specific antigen screening among young men in the United States. Cancer 2008; 113: 1315-23.
12. Lamplugh M, Gilmore P, Quinlan T, Cornford P. PSA testing: are patients aware of what lies ahead? Ann R Coll Surg Engl 2006; 88: 284-8.
13. Vis AN, van der Kwast TH. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. BJU Int 2001; 88: 147-57.
14. Ries LA, Malbert D, Krapcho M. SEER Cancer Statistics Review, 1975-2005. Bethesda: National Cancer Institute. Avilable http://seer.cancer.gov/csr/1975_2005/. Based on November 2007 SEER data submission posted to the SEER web site 2008.
15. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in he US prostate cancer mortality decline. Cancer Causes Control 2008; 19: 175.
16. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101.
17. Sandblom G, Dufmats M, Varenhorst E. Long-term survival in a Swedish population-based cohort of men with prostate cancer. Urology 2000; 56: 442-7.
18. American Cancer Society. Facts and Figures. Available at: http://www-cancer.org/downloads/STT/CAFF2006PWSecured.pdf. [Accessed July 2008].
19. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94.
20. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004: 350(22): 2239-46.
21. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostatespecific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860.
22. Hakama M, Auvinen A. Cancer screening. In: Heggenhougen K, Quah SR, Eds. International encyclopedia of public health. San Diego, CA: Academic Press, 2008; pp. 464-80.
23. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA 2004; 291: 2713-9.
24. Sakr WA, Grignon DJ, Crissman JD, et al. High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. In Vivo 1994; 8: 439-43.
25. Roemeling S, Roobol MJ, Kattan MW, van der Kwast TH, Steyerberg EW, Schroder FH. Nomogram use for the prediction of indolent prostate cancer: impact on screen-detected populations. Cancer 2007; 110: 2218-21.
26. van Leeuwen PJ, Connolly D, Gavin A, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefits. Eur J Cancer 2010; 46(2): 377-83.
27. Otto SJ, van der Cruijsen IW, Liem MK, et al. Effective PSA contamination in the rotterdam section of the european randomized study of screening for prostate cancer. Int J Cancer 2003; 105(3): 394-9.
28. Ciatto S, Zappa M, Villers A, Paez A, Otto SJ, Auvinen A. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening. BJU Int 2003; 92(Suppl.2): 97-100.
29. Canfield SE. Annual screening for prostate cancer did cot reduce mortality from prostate cancer. Evid Based Med 2009; 14; 104-105.
30. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998; 317(7154): 307-12.
31. Barry MJ. Screening for Prostate Cancer-The controversy that Refuses to Die. N Engl J Med 2009; 360(13): 1351-4.
32. Roobol MJ, KerkhofM, Schroder FH, et al. Prostate cancer mortality reduction by prostate-specific antigen based screening adjusted for nonattendance and contamination in the European Randomized Study of screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56(4): 584-91.
33. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-29.
34. Thomas H. Lee, Mary F. McNaughton-Collins, Philip W. Kantoff. Perspective roundtable: screening for prostate cancer. N Engl J Med 2010; 1-5.
35. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78.
36. Fitzpatrick JM, Schulman C, Zlotta AR, Schroder FH. Prostate cancer: a serious disease suitable for prevention. BJU 2008; 103: 864-70.
37. Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol 2003; 22: 443-52.
38. Korfage IJ, Essink-Bot ML. Janssens AC, Schroder FH, de Koning HJ. Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up. Br J Cancer 2006; 94: 1093-8.
39. Stark JR, Mucci L, Rothman KJ, Adami HO. Prostate cancer screening: the controversy continues. BMJ 2009; 339: b3601.